Oblenio Bio secured $62 million in a Series B funding round led by Pfizer Ventures to support clinical development of LBL-051, a tri-specific T-cell engager targeting autoimmune diseases. LBL-051 aims to reset the immune system by depleting B-cells and plasma cells, potentially enabling long-term drug-free remission for patients. Preclinical data presented at EULAR 2026 showed promising safety and efficacy, with no cytokine release syndrome observed. The company plans to start first-in-human clinical trials soon, with new board members from Pfizer Ventures and Deep Track Capital joining to guide development.
Novo Nordisk reported a 4% sales decline in Q1 FY26 excluding a $4.2B accounting reversal, with key drugs Ozempic and Rybelsus dropping significantly. The company also announced major price cuts for Wegovy and Ozempic in 2027 and faced setbacks with ...
Eli Lilly reported a 55.5% revenue increase to $19.80B in Q1 2026, driven by obesity drugs Mounjaro and Zepbound, while Pfizer's revenue rose 5.4% to $14.45B, supported by Eliquis and oncology products but weighed down by declining COVID-related sale...
